News articles about Kadmon (NYSE:KDMN) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kadmon earned a news impact score of 0.15 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.6434326106034 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
A number of research analysts have weighed in on KDMN shares. Zacks Investment Research raised Kadmon from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research note on Friday, January 12th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Kadmon in a research report on Friday, December 15th. Jefferies Group increased their target price on Kadmon to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, February 13th. Finally, Piper Jaffray Companies reaffirmed a “positive” rating and issued a $9.00 target price (up from $7.00) on shares of Kadmon in a research report on Tuesday, February 13th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $10.21.
Shares of KDMN stock traded up $0.15 on Wednesday, hitting $4.40. The company had a trading volume of 436,850 shares, compared to its average volume of 1,079,783. The stock has a market cap of $333.45, a price-to-earnings ratio of -2.95 and a beta of 5.59. Kadmon has a twelve month low of $2.05 and a twelve month high of $5.86.
ILLEGAL ACTIVITY WARNING: “Kadmon (NYSE:KDMN) Given News Impact Rating of 0.15” was first published by BBNS and is the property of of BBNS. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://baseballnewssource.com/2018/03/21/kadmon-kdmn-earning-somewhat-favorable-media-coverage-study-shows/1923639.html.
Kadmon Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.